Nuvectis Pharma (NVCT) Times Interest Earned (2021 - 2026)
Nuvectis Pharma (NVCT) posted Times Interest Earned of -$5.72 for Q1 2026, up 22.55% sequentially from -$7.39 in Q4 2025, and down 85.39% YoY from -$39.17 in Q1 2025.
Nuvectis Pharma (NVCT) Times Interest Earned (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Times Interest Earned for 6 years, with the latest figure at -$5.72 in Q1 2026.
- Quarterly Times Interest Earned fell 85.39% year-over-year to -$5.72 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.84 (down 121.75% YoY) and the FY2025 annual result came in at -$26.74, down 2531.5% from the prior year.
- Times Interest Earned climbed to -$5.72 in Q1 2026 per NVCT's latest filing, from -$7.39 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.33 in Q4 2024 and troughed at -$15.65 in Q3 2025.
- A 5-year average of -$3.76 and a median of -$2.15 in 2022 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2025: Times Interest Earned surged 88.35% in 2023, then plunged 2137.13% in 2025.
- Over 5 years, Times Interest Earned stood at -$0.79 in 2022, then surged by 40.07% to -$0.47 in 2023, then surged by 30.3% to -$0.33 in 2024, then slumped by 2137.13% to -$7.39 in 2025, then grew by 22.55% to -$5.72 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$5.72, -$7.39, and -$15.65 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.72 |
| Dec 31, 2025 | -7.39 |
| Sep 30, 2025 | -15.65 |
| Jun 30, 2025 | -6.58 |
| Mar 31, 2025 | -3.09 |
| Dec 31, 2024 | -0.33 |
| Sep 30, 2024 | -7.36 |
| Jun 30, 2024 | -7.66 |
| Mar 31, 2024 | -0.46 |
| Dec 31, 2023 | -0.47 |
| Sep 30, 2023 | -0.50 |
| Jun 30, 2023 | -1.45 |
| Mar 31, 2023 | -0.35 |
| Dec 31, 2022 | -0.79 |
| Sep 30, 2022 | -2.15 |
| Jun 30, 2022 | -0.96 |
| Mar 31, 2022 | -2.98 |
| Dec 31, 2021 | -0.65 |